An inadequate glycaemic response to glucagon is linked to insulin resistance in preterm infants?

L Jackson1, A Burchell, A McGeechan

  • 1Department of Obstetrics and Gynaecology, Tayside Institute of Child Health, Ninewells Hospital and Medical School, University of Dundee, Scotland, UK.

Insights

Some preterm infants exhibit inadequate glucagon response, indicating potential insulin resistance. This finding highlights important public health considerations for infant metabolic health.

Area of Science:

  • Neonatalogy
  • Endocrinology
  • Metabolic Research

Background:

  • Preterm infants face unique metabolic challenges.
  • Understanding glucagon responsiveness is crucial for neonatal care.

Purpose of the Study:

  • To characterize clinical, metabolic, and hormonal differences in preterm infants based on glucagon responsiveness.
  • To identify factors associated with inadequate glycaemic response to glucagon in this population.

Main Methods:

  • A two-phase study involving 78 preterm infants (25-36 weeks gestation).
  • Phase 1: Fasting until hypoglycemia or 8 hours, followed by endocrine/metabolic profiling.
  • Phase 2: Glucagon administration (100 μg/kg IV) after feed omission, monitoring glucose and lactate levels.

Main Results:

  • Infants with inadequate glucagon response showed relative fasting hyperglycemia (3.7 vs 3.3 mmol/l).
  • They also exhibited fasting hyperinsulinemia (4.3 vs 2.6 mU/l) and higher insulin:glucagon ratio (0.19 vs 0.11).
  • Lower insulin sensitivity (QUICKI index) was observed in the inadequate response group (0.19 vs 0.22).

Conclusions:

  • Certain preterm infants display inadequate glycaemic response to glucagon, suggesting underlying insulin resistance.
  • These findings may have significant long-term public health implications regarding metabolic health in preterm infants.
Abstract

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.